Correction: HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th
January 23 2023 - 9:00AM
In a release issued under the same headline on January 20th, 2023,
by HeartSciences (NASDAQ: HSCS; HSCSW), please note that in the
second paragraph the fireside chat time was at 11:30 a.m.
Eastern Time should be corrected to 11:00 a.m. Eastern Time on
Wednesday, January 25th. The corrected release follows:
Heart Test Laboratories, Inc. d/b/a
HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the
“Company”), a medical technology company focused on saving lives by
making an ECG (also known as an EKG) a far more valuable screening
tool through the use of Artificial Intelligence (AI), today
announced that Andrew Simpson, Chief Executive Officer of
HeartSciences, will be participating in the Healthcare IT Virtual
Conference, presented by Maxim Group LLC and hosted by M-Vest,
being held virtually on Wednesday, January 25, 2023.
Mr. Simpson is scheduled to participate in a
fireside chat with analyst Allen Klee at 11:00 a.m. Eastern Time on
Wednesday, January 25th. To reserve your seat for the event, please
register for the conference here: Healthcare IT Virtual Conference
| M-Vest.
About HeartSciences
Heart Test Laboratories, Inc. d/b/a
HeartSciences is a medical technology company focused on applying
innovative AI-based technology to an ECG (also known as an EKG) to
expand and improve an ECG’s clinical usefulness. Millions of ECGs
are performed every week and the Company’s objective is to improve
healthcare by making an ECG a far more valuable cardiac screening
tool, particularly in frontline or point-of-care clinical settings.
HeartSciences’ first product candidate for FDA clearance, the
MyoVista® wavECG, or the MyoVista®, is a resting 12-lead ECG that
is also designed to provide diagnostic information related to
cardiac dysfunction which has traditionally only been available
through the use of cardiac imaging. The MyoVista® also provides
conventional ECG information in the same test. The business model,
which involves the use of the MyoVista® device and consumables for
each test, is expected to be “razor-razorblade” as the electrodes
used with the MyoVista® are proprietary to HeartSciences, and new
electrodes are required for every test performed.For more
information, please visit: https://www.heartsciences.com.
Twitter: @HeartSciencesSafe Harbor
StatementThis announcement contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are made under the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995
and are relating to the Company's future financial and operating
performance. All statements, other than statements of historical
facts, included herein are "forward-looking statements" including,
among other things, statements about HeartSciences’ beliefs and
expectations. These statements are based on current expectations,
assumptions and uncertainties involving judgments about, among
other things, future economic, competitive and market conditions
and future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond the
Company's control. The expectations reflected in these
forward-looking statements involve significant assumptions, risks
and uncertainties, and these expectations may prove to be
incorrect. Investors should not place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Potential risks and uncertainties include, but are
not limited to, risks discussed in HeartSciences’ filings with the
U.S. Securities and Exchange Commission at www.sec.gov. Other than
as required under the securities laws, the Company does not assume
a duty to update these forward-looking statements.For
investor and media inquiries, please contact:Investor
Relations:Crescendo Communications, LLCPhone: (212) 671-1021Email:
HSCS@crescendo-ir.com
Company: Gene Gephart Phone: +1-737-414-9213 (US) Email:
investorrelations@heartsciences.com
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Heart Test Laboratories (NASDAQ:HSCS)
Historical Stock Chart
From Apr 2023 to Apr 2024